An essential type i nitroreductase from leishmania major can be used to activate leishmanicidal prodrugs

Journal of Biological Chemistry

Volumn 288, Issue 40, 2013, Pages 28466-28476

  Voak, Andrew A ^a,b   Gobalakrishnapillai, Vithurshaa ^a   Seifert, Karin ^b   Balczo, Edina ^a,d   Hu, Longqin ^c   Hall, Belinda S ^a,e   Wilkinson, Shane R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c RUTGERS UNIVERSITY   (United States)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL CHARACTERISTICS; DRUG DEVELOPMENT; INHIBITOR DESIGN; LEISHMANIA MAJOR; NITROREDUCTASES; PARASITE GROWTH; PRODRUG ACTIVATION; TROPICAL DISEASE;

BIOCHEMISTRY; BIOLOGY;

DEVELOPING COUNTRIES;

ANTIPROTOZOAL AGENT; BENZNIDAZOLE; DUROQUINONE; LEISHMANICIDAL; METRONIDAZOLE; NIFURTIMOX; NITROBENZYLPHOSPHORAMIDE MUSTARD; NITROFURAL; NITROFURANTOIN; NITROREDUCTASE; OXIDOREDUCTASE; PRODRUG; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE); TRETAZICAR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE CARRIER; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG METABOLISM; FEMALE; GENE DELETION; HETEROZYGOTE; HUMAN; HUMAN CELL; LEISHMANIA MAJOR; LEISHMANICIDAL ACTIVITY; MALE; MAMMAL CELL; METACYCLIC CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN EXPRESSION;

DRUG DISCOVERY; DRUG SCREENING; OXIDATION-REDUCTION; PARASITE; TRYPANOSOMA BRUCEI; TRYPANOSOME;

ALLELES; ANIMALS; CELL DIFFERENTIATION; CELL LINE; ENZYME INHIBITORS; FEMALE; FLAVIN MONONUCLEOTIDE; HETEROZYGOTE; HUMANS; KINETICS; LEISHMANIA MAJOR; MICE; MICE, INBRED BALB C; MUSTARD COMPOUNDS; NITROIMIDAZOLES; NITROREDUCTASES; PRODRUGS; SUBSTRATE SPECIFICITY; TRYPANOCIDAL AGENTS;

EID: 84885133193     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.494781     Document Type: Article

References (50)

1. Stuart, K., Brun, R., Croft, S., Fairlamb, A., Gürtler, R. E., McKerrow, J., Reed, S., and Tarleton, R. (2008) Kinetoplastids: related protozoan pathogens, different diseases. J. Clin. Invest. 118, 1301-1310
2. Cruz, I., Morales, M. A., Noguer, I., Rodríguez, A., and Alvar, J. (2002) Leishmania in discarded syringes from intravenous drug users. Lancet 359, 1124-1125
3. González, C., Wang, O., Strutz, S. E., González-Salazar, C., Sánchez-Cordero, V., and Sarkar, S. (2010) Climate change and risk of leishmaniasis in North America: predictions from ecological niche models of vector and reservoir species. PLoS Negl. Trop. Dis. 4, e585
4. Pavli, A., and Maltezou, H. C. (2010) Leishmaniasis, an emerging infection in travelers. Int. J. Infect. Dis. 14, e1032-1039
5. Croft, S. L., Sundar, S., and Fairlamb, A. H. (2006) Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19, 111-126
6. Croft, S. L., and Olliaro, P. (2011) Leishmaniasis chemotherapy- challenges and opportunities. Clin. Microbiol. Infect. 17, 1478-1483
7. Balasegaram, M., Balasegaram, S., Malvy, D., and Millet, P. (2008) Neglected diseases in the news: a content analysis of recent international media coverage focussing on leishmaniasis and trypanosomiasis. PLoS Negl. Trop. Dis. 2, e234
8. Grunberg, E., and Titsworth, E. H. (1973) Chemotherapeutic properties of heterocyclic compounds: monocyclic compounds with five-membered rings. Annu. Rev. Microbiol. 27, 317-346
9. McCalla, D. R. (1983) Mutagenicity of nitrofuran derivatives: review. Environ. Mutagen. 5, 745-765
10. Takahashi, M., Iizuka, S., Watanabe, T., Yoshida, M., Ando, J., Wakabayashi, K., and Maekawa, A. (2000) Possible mechanisms underlying mammary carcinogenesis in female Wistar rats by nitrofurazone. Cancer Lett. 156, 177-184
11. Hiraku, Y., Sekine, A., Nabeshi, H., Midorikawa, K., Murata, M., Kumagai, Y., and Kawanishi, S. (2004) Mechanism of carcinogenesis induced by a veterinary antimicrobial drug, nitrofurazone, via oxidative DNA damage and cell proliferation. Cancer Lett. 215, 141-150
12. Trunz, B. B., Jȩdrysiak, R., Tweats, D., Brun, R., Kaiser, M., Suwiński, J., and Torreele, E. (2011) 1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis. Eur. J. Med. Chem. 46, 1524-1535
13. Tweats, D., Bourdin Trunz, B., and Torreele, E. (2012) Genotoxicity profile of fexinidazole-a drug candidate in clinical development for human African trypanomiasis (sleeping sickness). Mutagenesis 27, 523-532
14. Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., and Komatsu, M. (2006) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3, e466
15. Arya, S. C., and Agarwal, N. (2009) Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int. 103, 994-995
16. Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., Kreiswirth, B. N., Barry, C. E., and Baker, W. R. (2000) A smallmolecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962-966
17. Adagu, I. S., Nolder, D., Warhurst, D. C., and Rossignol, J.-F. (2002) In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica, and Trichomonas vaginalis. J. Antimicrob. Chemother. 49, 103-111
18. Korba, B. E., Montero, A. B., Farrar, K., Gaye, K., Mukerjee, S., Ayers, M. S., and Rossignol, J. F. (2008) Nitazoxanide, tizoxanide, and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 77, 56-63
19. Kaiser, M., Bray, M. A., Cal, M., Bourdin Trunz, B., Torreele, E., and Brun, R. (2011) Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob. Agents Chemother. 55, 5602-5608
20. Wyllie, S., Patterson, S., Stojanovski, L., Simeons, F. R., Norval, S., Kime, R., Read, K. D., and Fairlamb, A. H. (2012) The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci. Transl. Med. 4, 119re1
21. Denny, W. A. (2003) Prodrugs for gene-directed enzyme-prodrug therapy (Suicide Gene Therapy). J. Biomed. Biotechnol. 2003, 48-70
22. Saulnier Sholler, G. L., Kalkunte, S., Greenlaw, C., McCarten, K., and Forman, E. (2006) Antitumor activity of nifurtimox observed in a patient with neuroblastoma. J. Pediatr. Hematol. Oncol. 28, 693-695
23. Chen, Y., and Hu, L. (2009) Design of anticancer prodrugs for reductive activation. Med. Res. Rev. 29, 29-64
24. Peterson, F. J., Mason, R. P., Hovsepian, J., and Holtzman, J. L. (1979) Oxygen-sensitive and-insensitive nitroreduction by Escherichia coli and rat hepatic microsomes. J. Biol. Chem. 254, 4009-4014
25. Moreno, S. N., Mason, R. P., and Docampo, R. (1984) Reduction of nifurtimox and nitrofurantoin to free radical metabolites by rat liver mitochondria. Evidence of an outer membrane-located nitroreductase. J. Biol. Chem. 259, 6298-6305
26. Wilkinson, S. R., Taylor, M. C., Horn, D., Kelly, J. M., and Cheeseman, I. (2008) A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. U.S.A. 105, 5022-5027
27. Pal, D., Banerjee, S., Cui, J., Schwartz, A., Ghosh, S. K., and Samuelson, J. (2009) Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob. Agents Chemother. 53, 458-464
28. de Oliveira, I. M., Henriques, J. A., and Bonatto, D. (2007) In silico identification of a new group of specific bacterial and fungal nitroreductases-like proteins. Biochem. Biophys. Res. Commun. 355, 919-925
29. Chen, S., Knox, R., Wu, K., Deng, P. S., Zhou, D., Bianchet, M. A., and Amzel, L. M. (1997) Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse. J. Biol. Chem. 272, 1437-1439
30. Hu, L., Yu, C., Jiang, Y., Han, J., Li, Z., Browne, P., Race, P. R., Knox, R. J., Searle, P. F., and Hyde, E. I. (2003) Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy. J. Med. Chem. 46, 4818-4821
31. Jiang, Y., Han, J., Yu, C., Vass, S. O., Searle, P. F., Browne, P., Knox, R. J., and Hu, L. (2006) Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation. J. Med. Chem. 49, 4333-4343
32. Jiang, Y., and Hu, L. (2008) N-(2,2-Dimethyl-2-(2-nitrophenyl)acetyl)-4- aminocyclophosphamide as a potential bioreductively activated prodrug of phosphoramide mustard. Bioorg. Med. Chem. Lett. 18, 4059-4063
33. Hu, L., Wu, X., Han, J., Chen, L., Vass, S. O., Browne, P., Hall, B. S., Bot, C., Gobalakrishnapillai, V., Searle, P. F., Knox, R. J., and Wilkinson, S. R. (2011) Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs. Bioorg. Med. Chem. Lett. 21, 3986-3991
34. da Silva, R., and Sacks, D. L. (1987) Metacyclogenesis is a major determinant of Leishmania promastigote virulence and attenuation. Infect. Immun. 55, 2802-2806
35. Rovera, G., O'Brien, T. G., and Diamond, L. (1979) Induction of differentiation in human promyelocytic leukemia cells by tumor promoters. Science 204, 868-870
36. Hall, B. S., Wu, X., Hu, L., and Wilkinson, S. R. (2010) Exploiting the drug-activating properties of a novel trypanosomal nitroreductase. Antimicrob. Agents Chemother. 54, 1193-1199
37. Race, P. R., Lovering, A. L., White, S. A., Grove, J. I., Searle, P. F., Wrighton, C. W., and Hyde, E. I. (2007) Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954. J. Mol. Biol. 368, 481-492
38. Faeder, E. J., and Siegel, L. M. (1973) A rapid micromethod for determination of FMN and FAD in mixtures. Anal. Biochem. 53, 332-336
39. Bryant, C., and DeLuca, M. (1991) Purification and characterization of an oxygen-insensitive NAD(P)H nitroreductase from Enterobacter cloacae. J. Biol. Chem. 266, 4119-4125
40. Zenno, S., Koike, H., Tanokura, M., and Saigo, K. (1996) Gene cloning, purification, and characterization of NfsB, a minor oxygen-insensitive nitroreductase from Escherichia coli, similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri. J. Biochem. 120, 736-744
41. Watanabe, M., Nishino, T., Takio, K., Sofuni, T., and Nohmi, T. (1998) Purification and characterization of wild-type and mutant "classical" nitroreductases of Salmonella typhimurium. L33R mutation greatly diminishes binding of FMN to the nitroreductase of S. typhimurium. J. Biol. Chem. 273, 23922-23928
42. Hall, B. S., Meredith, E. L., and Wilkinson, S. R. (2012) Targeting the substrate preference of a type I nitroreductase to develop antitrypanosomal quinone-based prodrugs. Antimicrob. Agents Chemother. 56, 5821-5830
43. Charest, H., Zhang, W. W., and Matlashewski, G. (1996) The developmental expression of Leishmania donovani A2 amastigote-specific genes is post-transcriptionally mediated and involves elements located in the 3-untranslated region. J. Biol. Chem. 271, 17081-17090
44. Hart, D. T., Vickerman, K., and Coombs, G. H. (1981) Respiration of Leishmania mexicana amastigotes and promastigotes. Mol. Biochem. Parasitol. 4, 39-51
45. Santhamma, K. R., and Bhaduri, A. (1995) Characterization of the respiratory chain of Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 75, 43-53
46. Van Hellemond, J. J., and Tielens, A. G. (1997) Inhibition of the respiratory chain results in a reversible metabolic arrest in Leishmania promastigote. Mol. Biochem. Parasitol. 85, 135-138
47. Opperdoes, F. R., and Michels, P. A. (2008) Complex I of Trypanosomatidae: does it exist? Trends Parasitol. 24, 310-317
48. Wyllie, S., Patterson, S., and Fairlamb, A. H. (2013) Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation. Antimicrob. Agents Chemother. 57, 901-906
49. Hall, B. S., Bot, C., and Wilkinson, S. R. (2011) Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J. Biol. Chem. 286, 13088-13095
50. Hall, B. S., and Wilkinson, S. R. (2012) Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob. Agents Chemother. 56, 115-123